←Back to Expert Scholars
Translational Medicine / 转化医学HER2 TKI NSCLC
Pasi Janne
MD, PhD
🏢Dana-Farber Cancer Institute🌐USA
Professor of Medicine
125
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Pasi Janne has driven translational lung cancer drug development including HER2-selective tyrosine kinase inhibitors for HER2 exon 20 insertion NSCLC. His work characterizes HER2 kinase structure and resistance biology in lung cancer. He continues to lead early-phase trials of novel HER2-selective and broad-spectrum TKIs.
Share:
🧪Research Fields 研究领域
HER2 TKI NSCLC
HER2 exon 20 biology
poziotinib DESTINY
HER2 kinase structure NSCLC
lung cancer drug development
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Pasi Janne 的研究动态
Follow Pasi Janne's research updates
留下邮箱，当我们发布与 Pasi Janne（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment